Cytoreduction of neuroendocrine tumors

Endocrine Surgery

Volumn , Issue , 2003, Pages 671-683

  Ahlman, Håkan ^a   Olausson, Michael ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947181903     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (78)

1. Williams E, Sandler M. The classification of carcinoid tumours. Lancet 1963; 1:238.
2. Capella C, Heitz P, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994; 55:11-23.
3. Jakobsen AM, Andersson P, Saglik G, Andersson E, Kölby L, Erickson JD, Forssell-Aronsson E, Wängberg B, Ahlman H. Differential expression of vesicular monoamine transporter (VMAT)1 and 2 in gastrointestinal endocrine tumours. J Pathol 2001; 195:463-472.
4. Rindi G, Azzoni C, La Rosa S, Klersy S, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999; 116:532-542.
5. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934-944.
6. Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H. Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases. Am J Surg Pathol 1998; 22:526-537.
7. Clark R, Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology 1998; 12:647-658.
8. Rosai J, Higa E. Mediastinal endocrine neoplasm of probable thymic origin, related to a carcinoid tumor Clinicopathologic study of 8 cases. Cancer 1972; 29: 1061-1074.
9. Ahlman H, Åhlund L, Dahlström A, Martner J, Stenqvist O, Tylén U. The use of SMS 201-995 and provocation tests in carcinoid patients in preparation for surgery and hepatic arterial embolisation. Anesth Analg 1988; 67:1142-1148.
10. Ahlman H, Wängberg B, Nilsson O, Grimelius L, Granérus G, Modlin IM, Stenqvist O, Scherstén T. Aspects of diagnosis and treatment of the foregut carcinoid syndrome. Scand J Gastroent 1992; 27:459-471.
11. Owen R. Anesthetic consideration in endocrine surgery. Anesthesia 1986; 41:71.
12. Kimmig B, Adolph J. Eisenhut selektive nuklearmedizinische Therapie mit MIBG. In: Zum Winkel K, ed. Wirkungssteigerung der Strahlentherapie maligner Tumoren. Berlin: Springer-Verlag, 1987:116-123.
13. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheo-chromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988; 109:267-273.
14. Moertel CG. An odyssey in the land of small intestinal tumours. J Clin Oncol 1987; 5:1502-1522.
15. Rothmund M, Kisker O. Surgical treatment of carcinoid tumours of the small bowel appendix colon and rectum. Digestion 1994; 55(suppl 3):86-91.
16. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994; 55(suppl 3):98-103.
17. Makridis C, Öberg K, Juhlin C, Rastad J, Johansson H, Lörelius LE, Åkerström G. Surgical treatment of midgut carcinoid tumors. World J Surg 1990; 14:377-385.
18. Wängberg B, Westberg G, Tylén U, Tisell LE, Jansson S, Nilsson O, Johanson V, Schersten T, Ahlman H. Survival of patients with disseminated midgut carcinoid tumours after aggressive tumour reduction. World J Surg 1996; 20:892-899.
19. Ahlman H, Kölby L, Lundell L, Olbe L, Wängberg B, Granérus G, Grimelius L, Nilsson O. Clinical management of gastric carcinoid tumors. Digestion 1994; 55 (suppl 3): 77-85.
20. Tisell LE, Ahlman H, Jansson S, Grimelius L. Total pancreatectomy in the MEN-1 syndrome. Br J Surg 1988; 75:154-157.
21. Evans DB, Skibber JM, Lee JE, Cleary KR, Ajani JA, Gagel RF, Sellin RV, Fenoglio CJ, Merrell RC, Hickey RC. Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993; 114:1175-1182.
22. Prinz RA, Badrinath K, Chejfec G, Freeark RJ, Greenlee HB. “Nonfunctioning” islet cell carcinoma of the pancreas. Am J Surg 1983; 49:345-349.
23. Chughtai TS, Morin JE, Sheiner NM, Wilson JA, Mulder DS. Bronchial carcinoid—twenty years experience defines a selective surgical approach. Surgery 1997; 122:801-808.
24. Sutliff VE, Doppman JL, Gibril LF. Growh of newly diagnosed untreated metastatic gastrinomas and predictors of growth pattern. J Clin Oncol 1997; 15:2420-2431.
25. Benjamin IS. Management of secondary endocrine tumours of the liver. In: Lynn J, Bloom SR, eds. Surgical Endocrinology. Oxford: Butterworth-Heinemann, 1993: 538-547.
26. Farges O, Belghiti J. Options in the resection of endocrine liver metastases. In: Mignon M, Colombel JF, eds. Recent Advances in the Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumours. Paris: John Libbey Eurotext, 1999: 335-337.
27. Miller CA, Ellison EC. Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin North Am 1998; 7:863-879.
28. Foster JH, Lundy J. Liver metastases. Curr Probl Surg 1981; 18:157-202.
29. Mc Entee GP, Nagorney DM, Kvols LK, Moertel CG, Grant CS. Cytoreductive hepatic surgery for neuroendocrine tumours. Surgery 1990; 108:1091-1096.
30. Galland RB, Blumgart LH. Carcinoid syndrome: surgical management. Br J Hosp Med 1986; 35(166):168-170.
31. Hughes KS, Sugarbaker PH. Resection of the liver for metastatic solid tumors. In: Rosenberg SA, ed. Surgical Treatment of Metastatic Cancer. Philadelphia: Lippin-cott, 1987:125-164.
32. Soreide O, Berstad T, Bakka A, Schrumpf E, Hanssen LE, Engh V, Bergan A, Flatmark A. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992; 111:48-54.
33. Carty SE, Jensen RT, Norton JA. Prospective study of aggressive resection of metastatic pancreatic endocrine tumours. Surgery 1992; 112:1024-1032.
34. Que FG, Nagorney DM, Batts KP, Linzl J, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995; 169:36-43.
35. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastastic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 1996; 20:908-915.
36. Ahlman H, Wängberg B, Tisell LE, Nilsson O, Fjaling M, Forssell-Aronsson E. Clinical efficacy of octreotide scintigraphy in patients with midgut carcinoid tumours and evaluation of intraoperative scintillation detection. Br J Surg 1994; 81:1144-1149.
37. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, Ahlman H. Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002; 26:998-1004.
38. Norton JA, Sugarbaker PH, Doppman JL, Wesley RA, Maton PN, Gardner JD, Jensen RT. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986; 203:352-359.
39. Markowitz JC. The hepatic artery. Surg Gynecol Obstet 1952; 95:644-646.
40. Gelin LE, Lewis D, Nilsson L. Liver blood flow in man during abdominal surgery II. The effect of hepatic artery occlusion on the blood flow through metastatic tumor nodules. Acta Hepatosplenol 1968; 15:21-24.
41. Cho KJ, Reuter SR, Schmidt R. Effects of experimental hepatic artery embolization on hepatic function. Am J Roentgenol 1976; 127:563-567.
42. Moertel CG, Johnson CM, McKusick MA, Martin JK Jr, Nagorney DM, Kvols LK, Rubin J, Kunselman S. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994; 120:302-309.
43. Geterud K, Tylén U, Jansson S, Stenqvist O, Tisell LE, Ahlman H. Hepatic arterial embolization in the treatment of the midgut carcinoid syndrome and other advanced endocrine tumours metastatic to the liver. J Intervent Radiol 1990; 5:69-76.
44. Almersjö O, Bengmark S, Engevik L, Hafstrom LO, Nilsson LA. Hepatic artery ligation as pretreatment for liver resection of metastatic cancer. Rev Surg 1966; 23: 377-380.
45. Chuang VP, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. Radiology 1981; 140:51-58.
46. Ajani JA, Carrasco CH, Wallace S. Neuroendocrine tumors metastatic to the liver vascular occlusion therapy. Ann NY Acad Sci 1994; 733:479-487.
47. Allison DJ, Modlin IM, Jenkins WJ. Treatment of carcinoid liver metastases by hepatic-artery embolisation. Lancet 1977; 2:1323-1325.
48. Pueyo I, Jimenez JR, Hernandez J, Brugarolas A, Garcia-Moran M, Garcia-Muniz JI, Arroyo F. Carcinoid syndrome treated by hepatic embolization. Am J Roentgenol 1978; 131:511-513.
49. Lunderquist A, Ericsson M, Nobin A, Sandin G. Gel-foam powder embolization of the hepatic artery in liver metastases of carcinoid tumor. Radiologie 1982; 22:65-70
50. Carrasco CH, Charnsangavej C, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolisation. Am J Roentgenol 1986; 147:149-154.
51. Hajarizadeh H, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemother-apy/chemoembolization combined with octreotide acetate. Am J Surg 1992; 163:479-483.
52. Venook AP, Stagg RJ, Lewis BJ, Chase JL, Ring EJ, Maroney TP, Hohn DC. Chemoembolization for hepatocellular carcinoma. J Clin Oncol 1990; 8:1108-1114.
53. Perry LJ, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumours. Surgery 1994; 116:1111-1116.
54. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M. Hepatic arterial chemoembolisation in patients with liver metastases of endocrine tumors. Cancer 1993; 71:2624-2630.
55. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35:1637-1644.
56. Nobin A, Mansson H, Lunderquist A. Evaluation of temporary liver dearterialization and embolization in patients with metastatic carcinoid tumor. Acta Oncol 1989; 28:419-424.
57. Wängberg B, Geterud K, Nilsson O, Jansson S, Dahlstrom A, Tylén U, Ahlman H. Embolisation therapy in the midgut carcinoid syndrome—just tumour ischemia? Acta Oncol 1993; 32:251-256.
58. Wangberg B, Ahlman H, Tylen U, Nilsson O, Her-modsson S, Hellstrand K. Accumulation of natural killer cells after hepatic artery embolisation in the midgut carcinoid syndrome. Br J Cancer 1995; 71:617-618.
59. Coupe MO, Hodgson HJF, Hemingway A, Allison DJ. The effect of hepatic artery embolization on survival in the carcinoid syndrome. J Intervent Radiol 1989; 4: 179.
60. Mitty HA, Warner RRP, Neuman LH, Train JS, Parnes IH. Control of carcinoid syndrome with hepatic artery embolization. Radiology 1985; 155:1623-1626.
61. Marlink RG, Lokich T, Robins SR, Clouse ME. Hepatic arterial embolization for metastatic hormone-secreting tumors: technique, effectiveness and complications. Cancer 1990; 64:2227-2232.
62. Hanssen LE, Schrumpf E, Kolbenstvedt AN, Tausjo J, Dolva LO. Treatment of malignant metastatic midgut carcinoid tumours with recombinent human a-2b-inter-feron with or without prior hepatic artery embolization. Scand J Gastroenterol 1989; 24:787-795.
63. Kölby L, Persson G, Franzén S, Ahrén B, for the Swedish MRC Group on Endocrine Abdominal Tumours. Effect of interferon-alpha on survival in patients with disseminated midgut carcinoid tumours—a prospective randomised study. In press.
64. 1-octreotide. Br J Cancer 1996; 73:770-775.
65. Scherstén T, Ahlman H, Wängberg B, Granérus G, Grimelius L. Hyperthermic liver perfusion chemotherapy in the treatment of the foregut carcinoid syndrome. Lancet 1991; 338:568-569.
66. Kölby L, Wängberg B, Ahlman H, Jansson S, Forssell-Aronsson E, Erickson JD, Nilsson O. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion 1998; 59:160-166.
67. Charnley RM, Doran J, Morris DL. Cryotherapy for liver metastases; a new approach. Br J Surg 1989; 76: 1040-1041.
68. Bilchik AJ, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997; 122:1040-1048.
69. Cozzi PJ, Englund R, Morris DL. Cryotherapy treatment of patients with hepatic metastases from neuroendocrine tumors. Cancer 1995; 76:501-509.
70. Dowlatshahi K, Bhattacharya AK, Silver B, Motalen T, Williams JW. Percutaneous interstitial laser therapy of a patient with recurrent hepatoma in a transplanted liver. Surgery 1992; 112:303-606.
71. Bilchik AJ, Rose DM, Allegra DP, Bostick PJ, Hsueh E, Morton DL. Radio frequency ablation: a normally invasive technique with multiple applications. Cancer J Sci Am 1999; 6:356-361.
72. Matsui Y, Nakagawa A, Kamiyama Y, Yamamoto K, Kubo N, Nakase Y. Selective thermocoagulation of unresectable pancreatic cancers by using radiofrequency capacitive heating. Pankreas 2000; 1:14-20.
73. Kettenbach J, Silverman SG, Hata N, Kuroda K, Saiviroonpurn P, Zientara GP, Morrison PR, Hushek SG, Black PM, Kikinis R, Jolesz FA. Monitoring and visualization techniques for MR-guided laser ablations in an open MR system. J Magn Reson Imaging 1998; 8: 933-943.
74. 1-octreotide. J Nucl Med 1996; 37:2002-2006.
75. Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, De Herder WW, Valkema R, Kwekke-boom DJ. Somatostatin receptor: scintigraphy and radionuclide threapy. Digestion 1996; 57(suppl 1):57-61.
76. Smith MC, Liu J, Chen T, Schrau H, Yeh CM, Jamav F, Valkema R, Bakker W, Kvols L, Krenning E, Pauwels S. OctreoTher: ongoing early clinical development of a somatostatin receptor—targeted radionuclide for antineoplastic therapy. Digestion 2000; 62(suppl 1):69-72.
77. Goldman JM, Melo JV. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1084-1086.
78. Chaudhry A, Papanicolaou V, Öberg K, Heldin CH, Funa K. Expression of platelet-derived growth factor and its receptors in neuroendorine tumors of the digestive system. Cancer Res 1992; 52:1006-1012.